Answers are grounded in this paper and cite their sources.
Gastric cancer (GC) therapies are limited by severe adverse effects. Galangin, a natural flavonoid from galangal, shows anticancer activity, but its efficacy and mechanisms against GC remain incompletely defined. We evaluated galangin against GC in vitro and in vivo, focusing on PI3K/AKT/mTOR signaling. Galangin inhibited proliferation and migration of SNU719 and MKN45 cells while sparing GES-1 epithelial cells. In xenografts, galangin (60–120 mg/kg/day) significantly and dose-dependently suppressed tumor growth. Galangin elevated intracellular reactive oxygen species (ROS), reduced mitochondrial membrane potential, and triggered caspase-3 activation and mitochondrial apoptosis. Transcriptomic and network pharmacology analyses implicated PI3K/AKT/mTOR, apoptosis, cell cycle, and p53 pathways; immunoblotting and immunohistochemistry confirmed pathway inhibition in cells and tumors, respectively. These findings support galangin as a multitarget anti-GC candidate with a favorable safety profile relative to 5-FU.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: